Phil Rivers' PR00012 Completes First Patient Dosing with No DLTs Observed, Marking Key Phase I Trial Milestone

2025-04-20

Beijing, April 20, 2025 — Dr. Jianfei Yang, President of R&D and Chief Scientific Officer of Beijing Phil Rivers Technology and Shenzhen Phil Rivers Biotechnology, announced that PR00012, an inno···...[Read more]

Revolutionary AI-Powered PR00012 Marks New Hope in Pancreatic Cancer Treatment, Receives IND Approval

2024-11-26

Phil Rivers Technology today announced that its breakthrough candidate drug PR00012 has received clinical trial approval from the National Medical Products Administration (NMPA) Center for Drug Evalua···...[Read more]

Senior immunologist Dr. Jianfei Yang joined PHIL RIVERS Technology as Chief Scientific Officer and debuted JPM Week

2023-01-11

Recently, Phil Rivers Technology (Beijing) Ltd. announced that Dr. Jianfei Yang has officially joined Phil Rivers Technology as Chief Scientific Officer (CSO). In view of the unique insights generated···...[Read more]

CAPR2022 | Phil Rivers Invited to Share New Practice of "AI+ Disease"

2022-09-27

In recent years, the topic of AI drug development has received extensive attention.The successful application cases and development prospects of AI technologies in other industries have triggered grea···...[Read more]

2022 Hefei Scenario Innovation Conference | Phil Rivers annual best scenario Award

2022-09-20

On September 16, 2022, the 1st China (Hefei) Scenario Innovation Conference sponsored by Hefei Municipal People's Government and Great Wall Strategic Consulting and organized by Hefei Development ···...[Read more]

NIB | Phil Rivers won the award for Biomedical "Rising Star"

2022-09-10

On September 7, 2022, the award ceremony of " Rising Star" of biomedicine will be held in Zhangjiang AI Island(AIsland).. Liu Ping, deputy director of the shanghai municipal commission of ec···...[Read more]

CSDR and Relevant Units to Investigate "Computational Medicine"

2022-08-29

CSDR and Relevant Units to Investigate "Computational Medicine"...[Read more]

2022 Suzhou Dialogue | Phil Rivers Zhao Yu was invited to give an opening speech

2022-08-29

On August 26, 2022, the special session "Production Quality Management in the Whole Life Cycle of Drugs and Packaging", organized by Huiyu Research Institute Of Pharmaceutical Packaging Tech···...[Read more]

2022 dTrial | Phil Rivers's virtual clinical trials application cases

2022-08-22

From August 19 to 20, 2022, DIA China Digital Clinical Trial Innovation Forum (dTrial Forum) was held in Suzhou Taihu Internation Conference Center. Zhao Yu, co-founder of Phil Rivers Technology, was ···...[Read more]

2nd AI Drug R&D Conference | Phil Rivers’s Digital Testing Ground for Drug Development Makes a Wonderful Appearance

2022-08-15

On August 10-11, 2022, the "Second AI Drug R & D Conference and AI Intelligent Drug Assisted Healthy China Theme Summit" was successfully held in Shanghai, China. A total of four major v···...[Read more]